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1343NT-proBNP levels, measured during follow-up, does not neces-
sarily correlate with the severity of the initial disease and that
NT-proBNP levels change, in a different way, according to the
underlying disease. This ﬁnding is surprising. In fact, although
a higher NT-proBNP is likely in adults with Fontan circulation and
a systemic right ventricle, it is unexpected the ﬁnding of either a
higher NT-proBNP in adult patients after atrial defect closure or of
normal levels in patients undergoing arterial switch or aortic
coarctation repair, at long-term follow-up (1,4–7).
The ﬁnal lesson is that absolute NP levels must be read in the
context of the speciﬁc CHD and from the perspective of the in-
dividual patient’s outcome. The NT-proBNP plasma level mirrors
the inﬂuence of diverse factors and is an expression not only of
hemodynamic overload on either the right or left heart, but also of
noncardiac confounders, such as age and sex (with the need to
adapt reference values throughout the patient’s life span) (4,5), as
well as others that have not been taken into account in this work
such as renal function and neurohormonal activation (9). There-
fore, the measurement of cardiac endocrine function should be
considered as part of a multimarker approach, including reﬁned
echocardiographic or cardiac magnetic resonance evaluation and
assessment of functional capacity by means of cardiopulmonary
stress testing aimed at the most objective therapeutic decision
making, in particular at the evaluation of timing of surgical redo.*Massimiliano Cantinotti, MD
Aldo Clerico, MD
Michele Emdin, MD, PhD
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We thank Dr. Cantinotti and colleagues for their response to our
paper (1) describing the clinical usefulness of N-terminal pro–B-
type natriuretic peptide (NT-proBNP) in adults with congenital
heart disease (CHD) and showing correlations with echocardio-
graphic and exercise parameters.
As Dr. Cantinotti and colleagues state, the ﬁnding that the
NT-proBNP level was not correlated with the severity of the
initial disease was unexpected. NT-proBNP levels in patients with
surgically corrected atrial septal defects are known to be slightly
elevated (2). However, the remarkably low NT-proBNP levels in
patients after undergoing an arterial switch operation are surprising
and, together with their normal cardiac function and exercise
capacity, all mirror a good clinical condition. These are promising
factors for the long-term outcome of these patients. Because this is
the ﬁrst report of NT-proBNP in adults undergoing an arterial
switch operation and our study population was relatively small,
further research on these patients is clearly warranted.
We agree with Dr. Cantinotti and colleagues that absolute
NT-proBNP levels must be interpreted in the context of the in-
dividual patient characteristics. Noncardiac factors including age,
sex, and renal function are known to inﬂuence NT-proBNP levels
(3); therefore, patients with renal dysfunction were excluded from
our study, and in our statistical analyses, we adjusted for age and
sex. Nevertheless, all adults with CHD have a unique medical
history, with or without cyanosis and varying from no to multiple
surgical interventions, that may have inﬂuenced cardiac loading
conditions and consequent NT-proBNP release. Future research
should focus on the various CHDs in combination with patients’
medical history to improve interpretation of individual B-type
natriuretic peptide (BNP) results.
The production and excretion of BNP and NT-proBNP is a
complex process that is inﬂuenced by mechanical, neurohormonal,
and immunological factors (4), and novel cardiac biomarkers such
as ST2, galectin-3, and GDF-15 (5,6) have been gaining in in-
terest recently. Possibly, in the future, a multimarker approach
together with established diagnostic tools could improve decision
making in the specialist care of this unique patient population.Jannet A. Eindhoven, MD
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